160 related articles for article (PubMed ID: 3517241)
1. A comparison of mitoxantrone and doxorubicin in breast cancer.
Neidhart JA; Gochnour D; Roach R; Hoth D; Young D
J Clin Oncol; 1986 May; 4(5):672-7. PubMed ID: 3517241
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer.
Allegra JC; Woodcock T; Woolf S; Henderson IC; Bryan S; Reisman A; Dukart G
Invest New Drugs; 1985; 3(2):153-61. PubMed ID: 3894278
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Cowan JD; Osborne CK; Neidhart JA; Von Hoff DD; Constanzi JJ; Vaughn CB
Invest New Drugs; 1985; 3(2):149-52. PubMed ID: 3894277
[TBL] [Abstract][Full Text] [Related]
4. A comparative trial of mitoxantrone and doxorubicin in patients with minimally pretreated breast cancer.
Neidhart JA; Gochnour D; Roach RW; Young D; Steinberg JA
Semin Oncol; 1984 Sep; 11(3 Suppl 1):11-4. PubMed ID: 6385259
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone versus doxorubicin in advanced breast cancer: a randomized cross-over trial.
Neidhart JA; Gochnour D; Roach RW; Steinberg JA; Young D
Cancer Treat Rev; 1983 Dec; 10 Suppl B():41-6. PubMed ID: 6362877
[No Abstract] [Full Text] [Related]
6. First-line mitoxantrone chemotherapy for advanced breast cancer.
Wilson KS; Paterson AH
Cancer Treat Rep; 1986 Aug; 70(8):1021-2. PubMed ID: 3731148
[TBL] [Abstract][Full Text] [Related]
7. A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Bennett JM; Byrne P; Desai A; White C; DeConti R; Vogel C; Krementz E; Muggia F; Doroshow J; Plotkin D
Invest New Drugs; 1985; 3(2):179-85. PubMed ID: 3894279
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.
Henderson IC; Allegra JC; Woodcock T; Wolff S; Bryan S; Cartwright K; Dukart G; Henry D
J Clin Oncol; 1989 May; 7(5):560-71. PubMed ID: 2468745
[TBL] [Abstract][Full Text] [Related]
9. A randomized comparison of cyclophosphamide-mitoxantrone-5-fluorouracil v cyclophosphamide-doxorubicin-5-fluorouracil in advanced breast cancer: preliminary observations.
Stewart DJ; Maroun JA; Hirte W; Perrault D; Stolbach L; Cripps C; Lefebvre B
Semin Oncol; 1984 Sep; 11(3 Suppl 1):23-7. PubMed ID: 6385261
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone: a replacement for doxorubicin?
Conner CS
Drug Intell Clin Pharm; 1984 Jun; 18(6):479-80. PubMed ID: 6734434
[TBL] [Abstract][Full Text] [Related]
11. An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
De Jager R; Cappelaere P; Armand JP; Keiling R; Fargeot P; Bastit P; van Glabbeke M; Renard J; Earl H; Rubens R
Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1369-75. PubMed ID: 6542006
[TBL] [Abstract][Full Text] [Related]
12. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
[TBL] [Abstract][Full Text] [Related]
13. [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
Tominaga T; Kitamura M; Hayashi K; Takahashi I; Kosaki G
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1669-74. PubMed ID: 6591857
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
Metz R; Delgado M; Keiling R; Cappelaere P; Armand JP; Prevot G; Misset JL; Grimbert J; Mathe G
Invest New Drugs; 1985; 3(2):163-6. PubMed ID: 4019119
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity.
Coleman RE; Maisey MN; Knight RK; Rubens RD
Eur J Cancer Clin Oncol; 1984 Jun; 20(6):771-6. PubMed ID: 6540179
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours.
Stuart-Harris RC; Smith IE
Cancer Chemother Pharmacol; 1982; 8(2):179-82. PubMed ID: 7105382
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.
Mouridsen HT; Cornbleet M; Stuart-Harris R; Smith I; Coleman R; Rubens R; McDonald M; Rainer H; van Oosterom A; Smyth J
Invest New Drugs; 1985; 3(2):139-48. PubMed ID: 4019118
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone (novantrone): a review of experimental and early clinical studies.
Smith IE
Cancer Treat Rev; 1983 Jun; 10(2):103-15. PubMed ID: 6347376
[No Abstract] [Full Text] [Related]
19. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
[TBL] [Abstract][Full Text] [Related]
20. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
